1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022) Authors: Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; Beksaç, Meral; Legieć, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, Mar... Journal: Lancet Issue: Volume 9:Issue 6(2022) Page Start: e403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Issue 10373 (28th January 2023) Authors: Verstovsek, Srdan; Gerds, Aaron T; Vannucchi, Alessandro M; Al-Ali, Haifa Kathrin; Lavie, David; Kuykendall, Andrew T; Grosicki, Sebastian; Iurlo, Alessandra; Goh, Yeow Tee; Lazaroiu, Mihaela C; Egyed, Miklos; Fox, Maria Laura; McLornan, Donal; Perkins, Andrew; Yoon, Sung-Soo; Gupta, Vikas; Kilad... Journal: Lancet Issue: Volume 401:Issue 10373(2023) Page Start: 269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study. Issue 3 (23rd February 2019) Authors: Walewski, Jan; Paszkiewicz-Kozik, Ewa; Borsaru, Gabriela; Hellmann, Andrzej; Janikova, Andrea; Warszewska, Agnieszka; Mais, Anna; Ammendola, Astrid; Herz, Thomas; Krauss, Babett; Henning, Stefan W. Journal: Leukemia & lymphoma Issue: Volume 60:Issue 3(2019) Page Start: 675 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗